Labcorp Holdings (LH) is gaining momentum after launching its AI-powered MyLabcorp app, expanding specialty testing, and receiving an analyst upgrade for a stronger earnings outlook. Despite a recent share price decline, Simply Wall St projects Labcorp to be 16.2% undervalued with a fair value of $310.06 per share, driven by anticipated revenue growth from innovative tests and improved margins through AI technology. The company's focus on oncology, women's health, autoimmune disease, and neurology along with operational efficiencies from AI is expected to positively impact its valuation.
Diamond Hill Capital Management Inc. has reduced its stake in Labcorp Holdings Inc. by 23.3% but still holds a significant position of 1.26 million shares valued at $316.14 million, making Labcorp its 20th-largest holding. Labcorp reported better-than-expected quarterly results, with EPS of $4.25 and revenue of $3.54 billion, and raised its FY2026 EPS guidance. The company also declared a quarterly dividend of $0.72 per share and maintains a "Moderate Buy" analyst rating with an average target price of $308.
Handelsbanken Fonder AB has increased its stake in Labcorp Holdings Inc. (NYSE:LH) by 17.4% in the fourth quarter, bringing its total holding to 32,199 shares valued at $8.08 million. This increase follows Labcorp's strong Q4 earnings, which beat expectations with $4.25 EPS on $3.54 billion revenue, and raised its FY2026 guidance. Analyst sentiment remains positive with a "Moderate Buy" consensus and a target price of $308.00, alongside a declared quarterly dividend of $0.72 per share.
